17h
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and ...
Nat Clin Pract Neurol. 2007;3(9):505-516. Myoclonic Status Epilepticus. Myoclonic SE is characterized by continuous, usually generalized, myoclonias of cortical origin. The inclusion of myoclonic ...
extra on MSN9d
Waterford boy, 11, with ultra-rare condition spends months in hospital as he battles seizuresThe family of a Waterford boy who is the only person in Ireland with a rare disease have revealed how he can’t attend school ...
Canaccord initiated coverage of Ceribell (CBLL) with a Buy rating and $30 price target The firm views Ceribell as the pioneer and leader in ...
The co-primary endpoints were the proportion of patients with status epilepticus (SE) cessation within 30 minutes and the proportion of patients not progressing to IV anesthesia within 36 hours of ...
MyChesCo on MSN29d
Marinus Pharmaceuticals to Present New Epilepsy Treatment Data at Upcoming ConferenceRADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) is set to present significant findings from its Phase 3 RAISE trial ...
We’re exploring some of the most common triggers of seizure clusters and practical tips on how to avoid or manage these risks ...
Nonconvulsive status epilepticus (NCSE) encompasses a wide range of diagnoses with variable outcomes and treatment recommendations. In children, NCSE can be observed in various conditions ...
For those living with epilepsy, managing seizure clusters is a critical part of maintaining health and safety. Unlike isolated seizures, seizure clusters—defined as two or more seizures within a ...
UC's Brandon Foreman, MD, explained the trial focused on status epilepticus (SE), a disorder he described as "seizures that don't stop." Seizures are the second most common neurologic emergency in ...
This cleaner safety profile, demonstrated in preclinical studies, suggests that OV329 could offer a safer alternative for treating conditions like refractory status epilepticus and developmental ...
MyChesCo on MSN21d
Marinus Pharmaceuticals Unveils Promising Phase 3 Trial Results for IV Ganaxolone in Treating Refractory Status EpilepticusOne of the trial’s co-primary endpoints—cessation of status epilepticus (SE) within 30 minutes—was successfully met, with 80% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback